Asymmetric synthesis of (S)-phenylacetylcarbinol – closing a gap in C–C bond formation

Graphical abstract: Asymmetric synthesis of (S)-phenylacetylcarbinol – closing a gap in C–C bond formation

image file: c6gc01803c-f3.tif
Fig. 3 Stereoselectivities of the new ApPDC-variants for the synthesis of (S)-PAC. The different variants were tested as wet cells, crude cell extracts, and purified enzymes. Reaction conditions: wet cells – 20 mM benzaldehyde; 200 mM pyruvate; 50 mM KPi-buffer (pH 6.5), 2.5 mM MgSO4; 0.1 mM ThDP; 20 °C; 800 rpm, 800 μL reaction volume in 1.5 mL closed glass vials, whole cell catalyst concentration of 50 mg mL−1. Crude cell extract – 20 mM benzaldehyde; 200 mM pyruvate; 50 mM KPi-buffer (pH 6.5), 2.5 mM MgSO4; 0.1 mM ThDP; 20 °C; 800 rpm, 500 μL reaction volume in a 96-well sheet; see ESI chapter 2.1.4–2.1.5 for the catalyst concentration. Purified enzyme – 40 mM benzaldehyde; 200 mM pyruvate; 50 mM KPi-buffer with three different pH values, 2.5 mM MgSO4; 0.1 mM ThDP; 22 °C; 800 rpm, 800 μL reaction volume in 1.5 mL closed glass vials; protein concentration of 1 mg mL−1.

Asymmetric synthesis of (S)-phenylacetylcarbinol – closing a gap in C–C bond formation

*Corresponding authors
aInstitute of Bio- and Geosciences, IBG-1: Biotechnology, Forschungszentrum Jülich GmbH, Leo-Brandt-Str. 1, 52425 Jülich, Germany
E-mail: do.rother@fz-juelich.de
bHERBRAND PharmaChemicals GmbH, Brambachstr. 31, 77723 Gegenbach, Germany
cAlbaNova University Center, Royal Institute of Technology – School of Biotechnology, Roslagstull 21, Stockholm, Sweden
dInstitute of Pharmaceutical Sciences, Albert-Ludwigs-University Freiburg, Albertstrasse 25, 79104 Freiburg, Germany
eMerz Pharma GmbH & Co. KGaA, Am Pharmapark, D-06861 Dessau-Rosslau, Germany
fInstitute of Technical Biochemistry, University of Stuttgart, Allmandring 31, 70569 Stuttgart, Germany
gTRUMPF GmbH+Co.KG, Ditzingen Johann-Maus-Straße 2, 71254 Ditzingen, Germany
hEnzymicals AG, Walther-Rathenau-Str 49a, 17489 Greifswald, Germany
Green Chem., 2017,19, 380-384

DOI: 10.1039/C6GC01803C

(S)-Phenylacetylcarbinol [(S)-PAC] and its derivatives are valuable intermediates for the synthesis of various active pharmaceutical ingredients (APIs), but their selective synthesis is challenging. As no highly selective enzymes or chemical catalysts were available, we used semi-rational enzyme engineering to tailor a potent biocatalyst to be >97% stereoselective for the synthesis of (S)-PAC. By optimizing the reaction and process used, industrially relevant product concentrations of >48 g L−1 (up to 320 mM) were achieved. In addition, the best enzyme variant gave access to a broad range of ring-substituted (S)-PAC derivatives with high stereoselectivity, especially for meta-substituted products.

image file: c6gc01803c-f2.tif
Fig. 2 Schematic representation of the active site of ApPDC. The legends explain the effect of different amino acid residues on the preferred orientation of the ThDP-bound donor substrate acetaldehyde, derived from pyruvate after decarboxylation (green rectangle) and the aromatic acceptor aldehyde (blue hexagon). The relative orientation of both substrates to each other defines the stereoselectivity of the product. (The figures refer to the stereoselectivities achieved with purified enzyme.)

///////////////Asymmetric synthesis, (S)-phenylacetylcarbinol,  C–C bond formation

http://pubs.rsc.org/en/Content/ArticleLanding/2017/GC/C6GC01803C?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+rss%2FGC+%28RSC+-+Green+Chem.+latest+articles%29#!divAbstract

Advertisements

Asymmetric synthesis of (S)-phenylacetylcarbinol – closing a gap in C–C bond formation

 

Green Chem., 2017, Advance Article
DOI: 10.1039/C6GC01803C, Communication
Torsten Sehl, Saskia Bock, Lisa Marx, Zaira Maugeri, Lydia Walter, Robert Westphal, Constantin Vogel, Ulf Menyes, Martin Erhardt, Michael Muller, Martina Pohl, Dorte Rother
By the combination of biocatalyst design and reaction engineering, the so far not stereoselectively accessible (S)-phenylacetylcarbinol could be enzymatically synthesized with product concentrations >48 g L-1 and an enantiomeric excess up to 97%.
Asymmetric synthesis of (S)-phenylacetylcarbinol – closing a gap in C-C bond formation

Asymmetric synthesis of (S)-phenylacetylcarbinol – closing a gap in C–C bond formation

*Corresponding authors
aInstitute of Bio- and Geosciences, IBG-1: Biotechnology, Forschungszentrum Jülich GmbH, Leo-Brandt-Str. 1, 52425 Jülich, Germany
E-mail: do.rother@fz-juelich.de
bHERBRAND PharmaChemicals GmbH, Brambachstr. 31, 77723 Gegenbach, Germany
cAlbaNova University Center, Royal Institute of Technology – School of Biotechnology, Roslagstull 21, Stockholm, Sweden
d
Institute of Pharmaceutical Sciences, Albert-Ludwigs-University Freiburg, Albertstrasse 25, 79104 Freiburg, Germany
e
Merz Pharma GmbH & Co. KGaA, Am Pharmapark, D-06861 Dessau-Rosslau, Germany
f
Institute of Technical Biochemistry, University of Stuttgart, Allmandring 31, 70569 Stuttgart, Germany
g
TRUMPF GmbH+Co.KG, Ditzingen Johann-Maus-Straße 2, 71254 Ditzingen, Germany
h
Enzymicals AG, Walther-Rathenau-Str 49a, 17489 Greifswald, Germany
Green Chem., 2017, Advance Article

DOI: 10.1039/C6GC01803C

(S)-Phenylacetylcarbinol [(S)-PAC] and its derivatives are valuable intermediates for the synthesis of various active pharmaceutical ingredients (APIs), but their selective synthesis is challenging. As no highly selective enzymes or chemical catalysts were available, we used semi-rational enzyme engineering to tailor a potent biocatalyst to be >97% stereoselective for the synthesis of (S)-PAC. By optimizing the reaction and process used, industrially relevant product concentrations of >48 g L−1 (up to 320 mM) were achieved. In addition, the best enzyme variant gave access to a broad range of ring-substituted (S)-PAC derivatives with high stereoselectivity, especially for meta-substituted products.
str0

///////////Asymmetric synthesis, (S)-phenylacetylcarbinol, C-C bond formation